Age-based analysis of the SEC-Excelente-HF registry: clinical characteristics and prognosis of a prospective cohort of heart failure patients

Loading...
Thumbnail Image

Identifiers

Publication date

Authors

Esteban-Fernández, Alberto
Bonilla-Palomas, Juan Luis
González-Manzanares, Rafael
Anguita Gámez, María
Recio-Mayoral, Alejandro
Mirabet, Sonia
Cequier, Ángel
García Orta, Rocío
Anguita, Manuel

Advisors

Other responsabilities

Journal Title

Bibliographic citation

Esteban-Fernández A, Bonilla-Palomas JL, Muñiz J, González-Manzanares R, Anguita-Gámez M, Recio-Mayoral A, Mirabet S, Cequier Á, García-Orta R, Anguita-Sánchez M. Age-based analysis of the SEC-Excelente-HF registry: clinical characteristics and prognosis of a prospective cohort of heart failure patients. Eur Geriatr Med. 2026 Feb;17(1):273-281.

Type of academic work

Academic degree

Abstract

[Abstract] Background: Heart failure (HF) is highly prevalent in older adults with multiple comorbidities and geriatric syndromes, yet evidence on their management in structured HF units is limited. We assessed the clinical profile, treatment, and outcomes of older HF patients managed in accredited units in Spain. Methods: The SEC-Excelente-HF registry prospectively included 2,245 consecutive patients from 68 accredited HF units (2019-2023). Patients were stratified by age (< 75 years, n = 1267; ≥ 75 years, n = 973). Both hospitalized and outpatient patients were followed for 1 year. Data on demographics, comorbidities, therapies, and devices were collected. Primary outcomes were all-cause mortality, HF hospitalization, and their composite. Multivariable Cox models identified independent predictors of outcomes by age group. Results: Median age was 73 years, and 43.4% were ≥ 75 years. Older patients had higher prevalences of atrial fibrillation, valvular heart disease, chronic kidney disease, and anemia (all p < 0.001). Use of guideline-directed medical therapy was consistently lower in older patients, including RAAS inhibitors (69.2% vs 81.1%), beta-blockers (73.8% vs 87.1%), MRAs (46.2% vs 70.5%), and SGLT2 inhibitors (42.0% vs 62.4%; all p < 0.001). At 1 year, event-free survival was 66.3% in older vs 77.0% in younger patients (p < 0.001). In older patients, independent predictors of the composite outcome included prior HF, anemia, malnutrition, functional disability, advanced chronic kidney disease, and CRT/ICD implantation. Conclusions: Despite specialized care, older HF patients in accredited units exhibit a higher comorbidity burden, lower use of evidence-based therapies, and worse outcomes than younger patients. Enhanced multidisciplinary strategies are needed to improve prognosis in this growing population.

Description

Rights

This version of the article has been accepted for publication, after peer review and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at Springer Nature Link